Trial · NCT02911311
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
NCT02911311, Not applicable, Unknown, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy. Trials, record NCT02911311. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02911311
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
- NCT number
- NCT02911311
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 226 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- intravitreal injection of conbercept, PRP
- First posted
- 2016-09-22
- Last updated
- 2021-02-25
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The primary outcome is mean visual acuity change(BCVA) | 12 months | Primary outcome is the change in BCVA from screening to 12 moths in the study eye measured in the ETDRS letter score at 4 m |
| Secondary | Visual acuity outcomes in terms of visual gain or loss | 6 months and 12 months | visual gain refers to the proportion of visual improvement ≥ 15 letters at 6-month follow-up, visual loss refers to the proportion of visual reduction ≤ 15 letters at 6-month and 12-month follow-up |
| Secondary | the regression patterns of new vessels | 6 months and 12 months | the complete regression proportion of new retinal vessels is evaluated by the fundus photography and fundus fluorescein angiography at 6 months and 12 months |
| Secondary | proportion of patients developing macular oedema, vitreous haemorrhage and vitrectomy | 12 months | proportion of patients developing macular oedema, vitreous haemorrhage and vitrectomy at months |
| Secondary | change of visual field | 12 months | change of visual field will be evaluated by the perimeter |
| Secondary | change of retinal function | 12 months | change of retinal function measured by electroretinography(ERG) |
| Secondary | change of macular capillary density | 12 months | change of macular capillary density measured by Optical coherence tomography angiography |
| Secondary | change of central retinal thickness | 12 months | change of central retinal thickness measured by Optical coherence tomography |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26565927 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02911311
GET https://conductscience.org/api/trials/v1/NCT02911311/registered